NEW YORK (GenomeWeb News) – Affymetrix said after the close of the market on Wednesday that its second-quarter revenues climbed 20 percent year over year as product sales increased 27 percent on the addition of the eBioscience business.

Investors reacted positively to the results, sending Affy's shares up nearly 11 percent to $4.20 in Thursday morning trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.